These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38567555)

  • 1. Prognostic significance of antifibrotic agents in idiopathic pulmonary fibrosis after initiation of long-term oxygen therapy.
    Ishiwari M; Kono Y; Togashi Y; Kobayashi K; Kikuchi R; Kogami M; Abe S
    Sarcoidosis Vasc Diffuse Lung Dis; 2024 Mar; 41(1):e2024002. PubMed ID: 38567555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust.
    Casillo V; Cerri S; Ciervo A; Stendardo M; Manzoli L; Flacco ME; Manno M; Bocchino M; Luppi F; Boschetto P
    BMC Pulm Med; 2019 Sep; 19(1):170. PubMed ID: 31488107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy.
    Tahara M; Oda K; Yamasaki K; Kawaguchi T; Sennari K; Noguchi S; Sakamoto N; Kawanami T; Mukae H; Yatera K
    BMC Pulm Med; 2019 Aug; 19(1):157. PubMed ID: 31438928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly.
    Honda K; Saraya T; Ishii H
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.
    Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H
    Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis.
    de Andrade JA; Neely ML; Hellkamp AS; Culver DA; Kim HJ; Liesching T; Lobo LJ; Ramaswamy M; Safdar Z; Bender S; Conoscenti CS; Leonard TB; Palmer SM; Snyder LD;
    Clin Ther; 2023 Apr; 45(4):306-315. PubMed ID: 36997445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Tsurumaki H; Shin Y; Wakamatsu I; Kasahara N; Yamaguchi K; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Respir Investig; 2024 May; 62(3):388-394. PubMed ID: 38460356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
    Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
    Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis.
    Mochizuka Y; Suzuki Y; Kono M; Hasegawa H; Hashimoto D; Yokomura K; Inoue Y; Yasui H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura H; Suda T
    Respirology; 2023 Aug; 28(8):775-783. PubMed ID: 37221050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias.
    Arai T; Tachibana K; Sugimoto C; Inoue Y; Tokura S; Okuma T; Akira M; Kitaichi M; Hayashi S; Inoue Y
    Respirology; 2017 Oct; 22(7):1363-1370. PubMed ID: 28508494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
    Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
    Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study.
    Leuschner G; Klotsche J; Kreuter M; Prasse A; Wirtz H; Pittrow D; Frankenberger M; Behr J; Kneidinger N;
    Front Med (Lausanne); 2020; 7():601279. PubMed ID: 33313046
    [No Abstract]   [Full Text] [Related]  

  • 18. Fractal dimension in CT low attenuation areas is predictive of long-term oxygen therapy initiation in COPD patients: Results from two observational cohort studies.
    Ibaraki T; Tomoda K; Fujioka N; Sakaguchi K; Fujita Y; Yamamoto Y; Hontsu S; Yamauchi M; Yoshikawa M; Tanabe N; Tanimura K; Sato S; Saeki K; Muro S
    Respir Investig; 2022 Jan; 60(1):137-145. PubMed ID: 34583896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia.
    Sugino K; Ono H; Shimizu H; Kurosawa T; Matsumoto K; Ando M; Mori K; Tsuboi E; Homma S; Kishi K
    ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33681342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.